Mizuho lowered the firm’s price target on Veeva (VEEV) to $295 from $325 and keeps an Outperform rating on the shares. The firm trimmed targets in the healthcare technology space citing competitive risk.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV: